On March 25, 2016, Opexa Therapeutics, Inc. (NASDAQ: OPXA) entered into that certain Sales Agreement (the "Agreement") with IFS Securities, Inc. (doing business as Brinson Patrick, a division of IFS Securities, Inc.) (the "Sales Agent"), under...
NORTH CHICAGO (dpa-AFX) - An independent panel of experts convened by the
FDA has given Abbott's (ABT) 'Absorb fully bioresorbable drug eluting coronary
stent' positive review, voting 9 to 0, with one abstention that the...
Opexa Therapeutics is laying off 30% of its staff to conserve cash as it works through Phase IIb with a multiple sclerosis therapy, hoping to come through with positive results that can extend its runway.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.